Pacific Biosciences Of California (PACB) Accumulated Expenses (2011 - 2026)

Pacific Biosciences Of California's Accumulated Expenses history runs 16 years deep, the most recent figure standing at $33.9 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 15.57% year-over-year to $33.9 million; the TTM figure through Mar 2026 stood at $33.9 million (up 15.57% YoY), while the FY2025 annual figure was $33.6 million, up 48.91% from the prior year.
• Accumulated Expenses was $33.9 million for Q1 2026 at Pacific Biosciences Of California, up from $33.6 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $45.7 million in Q4 2023 to a low of $19.2 million in Q3 2024.
• Historically, Accumulated Expenses has averaged $27.5 million across 5 years, with a median of $26.5 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Accumulated Expenses surged 5387.54% in 2022, then tumbled 50.57% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $32.6 million in 2022, then soared by 40.23% to $45.7 million in 2023, then sank by 50.57% to $22.6 million in 2024, then soared by 48.91% to $33.6 million in 2025, then advanced by 0.77% to $33.9 million in 2026.
• The last three Accumulated Expenses figures came in at $33.9 million (Q1 2026), $33.6 million (Q4 2025), and $29.2 million (Q3 2025), per Business Quant data.